A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
DOI: 10.1016/j.euo.2021.12.006Author: Cyrill A. Rentsch et al.Published: 2022-4

Forum › Forums › Available Download: › DOI › A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14

DOI: 10.1016/j.euo.2021.12.006Author: Cyrill A. Rentsch et al.Published: 2022-4

Tagged: 

  • This topic is empty.
Viewing 1 post (of 1 total)
  • Author
    Posts
  • May 11, 2026 at 4:28 pm #1593
    marvinasciiMarvin ASCII
    Participant

    Title: A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non–muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14
    Journal: European Urology Oncology
    Authors: Cyrill A. Rentsch, George N. Thalmann, Ilaria Lucca, Maciej Kwiatkowski, Grégory J. Wirth, Räto T. Strebel, Daniel Engeler, Augusto Pedrazzini, Clemens Hüttenbrink, Wolfgang Schultze-Seemann, Raimund Torpai, Lukas Bubendorf, Andreas Wicki, Beat Roth, Piet Bosshard, Heike Püschel, Daniel T. Boll, Lukas Hefermehl, Florian Roghmann, Michael Gierth, Karin Ribi, Simon Schäfer, Stefanie Hayoz
    Date: 2022-4
    DOI: 10.1016/j.euo.2021.12.006
    Source: Elsevier BV
    Source URL: https://doi.org/10.1016/j.euo.2021.12.006

  • Author
    Posts
Viewing 1 post (of 1 total)
  • You must be logged in to reply to this topic.